Targeted KEAP1 disruption enhances antioxidant defense and mesenchymal stromal cell therapy for chronic limb-threatening ischemia
Molecular Therapy · 2026-07 · 34 (7) · 3949-3961
DOI: 10.1016/j.ymthe.2026.03.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026-07. Verfasst von Eun Ji Shin und 9 weiteren Autor:innen. Beteiligte Einrichtung: ToolGen, Inc., Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Kelch-Like ECH-Associated Protein 1, Mesenchymal Stem Cells, Mesenchymal Stem Cell Transplantation, Antioxidants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Ministry of Trade Industry and Energy, Samsung Medical Center, Korea Ministry of Health and Welfare.
Abstract (Originalsprache)
Chronic limb-threatening ischemia (CLTI) is a severe vascular disorder characterized by tissue hypoxia and oxidative stress that limit the efficacy of regenerative therapies. Mesenchymal stem/stromal cells (MSCs) hold promise for CLTI treatment through paracrine angiogenic and immunomodulatory signaling, yet their survival and function are compromised in the reactive oxygen species-rich ischemic microenvironment. Here, we utilized CRISPR-Cas9 to generate a targeted knockout of Kelch-like ECH-associated protein 1 (KEAP1), the negative regulator of the antioxidant transcription factor NRF2, in human bone marrow-derived MSCs. KEAP1 editing activated the NRF2 pathway, reduced intracellular oxidative stress, and reprogrammed redox and paracrine gene networks. Edited MSCs exhibited enhanced viability, sustained secretion of proangiogenic cytokines, and improved tissue perfusion and arteriogenesis in a murine model of CLTI. These findings establish KEAP1 gene editing as a permanent, integration-free strategy to augment MSC resistance and therapeutic efficacy in oxidative ischemic environments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ToolGen, Inc., Seoul, Republic of Korea.
- Cellartgen, Inc., Seoul 03722, Republic of Korea.
- Cellartgen, Inc., Seoul 03722, Republic of Korea; Department of Biotechnology, Yonsei University, Seoul 03722, Republic of Korea; Center for Nanomedicine, Institute for Basic Science (IBS), Seoul 03722, Republic of Kore…
- ToolGen, Inc., Seoul, Republic of Korea; Department of Health Science and Technology, Samsung Advanced Institute of Health Sciences and Technology (SAIHST), Sungkyunkwan University, Seoul 06351, Republic of Korea; Cell…
Förderung
- Korea Ministry of Trade Industry and Energy
- Samsung Medical Center
- Korea Ministry of Health and Welfare
- Sungkyunkwan University College of Science
- National Research Foundation of Korea
Zitieren
APA
Shin, E. J., Choi, Y., Jeon, E. J., Lee, K. I., Lee, K. J., Son, Y. J., Son, M. J., Kim, S., Cho, S. W., & Lee, J. Y. (2026). Targeted KEAP1 disruption enhances antioxidant defense and mesenchymal stromal cell therapy for chronic limb-threatening ischemia. Molecular Therapy, 34(7), 3949-3961. https://doi.org/10.1016/j.ymthe.2026.03.005
Vancouver
Shin EJ, Choi Y, Jeon EJ, Lee KI, Lee KJ, Son YJ, et al. Targeted KEAP1 disruption enhances antioxidant defense and mesenchymal stromal cell therapy for chronic limb-threatening ischemia. Molecular Therapy. 2026;34(7):3949-3961. doi:10.1016/j.ymthe.2026.03.005
BibTeX
@article{Shin2026,
author = {Shin, Eun Ji and Choi, Yuri and Jeon, Eun Je and Lee, Kang-In and Lee, Kyu-Jun and Son, Young Ju and Son, Min Ji and Kim, Seokjoong and Cho, Seung-Woo and Lee, Jae Young},
title = {Targeted KEAP1 disruption enhances antioxidant defense and mesenchymal stromal cell therapy for chronic limb-threatening ischemia},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {7},
pages = {3949--3961},
doi = {10.1016/j.ymthe.2026.03.005}
}
EUVIMED